Addex Therapeutics Ltd (SWX:ADXN)
0.0220
+0.0002 (0.92%)
Oct 2, 2026, 2:41 PM CET
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 9.95K CHF in the quarter ending June 30, 2026, a decrease of -72.65%. This brings the company's revenue in the last twelve months to 83.07K, down -50.34% year-over-year. In the year 2025, Addex Therapeutics had annual revenue of 172.86K, down -57.84%.
Revenue (ttm)
83.07K
Revenue Growth
-50.34%
P/S Ratio
31.31
Revenue / Employee
27.69K
Employees
3
Market Cap
2.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.86K | -237.18K | -57.84% |
| Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
| Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
| Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
| Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
| Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
| Dec 31, 2019 | 2.83M | -3.87M | -57.72% |
| Dec 31, 2018 | 6.70M | 6.20M | 1,240.82% |
| Dec 31, 2017 | 499.89K | 373.24K | 294.70% |
| Dec 31, 2016 | 126.65K | -348.97K | -73.37% |
| Dec 31, 2015 | 475.63K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 247.42M |
| Idorsia | 199.71M |
| Santhera Pharmaceuticals Holding AG | 101.50M |
| Newron Pharmaceuticals | 9.62M |
| BioVersys AG | 4.62M |
| MindMaze Therapeutics Holding | 1.20M |
| Molecular Partners AG | 681.00K |
Addex Therapeutics News
- 5 hours ago - Addex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix - Nasdaq
- 8 hours ago - Addex Therapeutics Announces Executive Management Changes - GlobeNewsWire
- 2 days ago - Addex Therapeutics (ADXN): Cash Runway and Returned GABAB Rights Set the Risk - AlphaStreet
- 3 days ago - Addex Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 3 days ago - Addex Therapeutics Quarterly report: Q2 2026 - Filings
- 3 days ago - Addex Therapeutics Earnings release: Q2 2026 - Filings
- 4 days ago - Addex Therapeutics (ADXN) Reports H1 2026 Losses, Cash Decline Amidst Challenging Market Valuation - GuruFocus
- 4 days ago - Addex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program - Nasdaq